Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
NCT00024635
Recruiting
The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evalua... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
08/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression, Mood Disorders, Anxiety Disorders, Healthy Volunteers, Bipolar Disorder
Register for Updates
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308
Recruiting
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/13/2025
Locations: U.S. Dermatology Partners - Rockville, Rockville, Maryland
Conditions: Alopecia Areata
Register for Updates
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262
Recruiting
The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.
Gender:
ALL
Ages:
Between 0 months and 36 months
Trial Updated:
08/13/2025
Locations: The Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Hypochondroplasia
Register for Updates
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459
Recruiting
This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Flourish Bowie, Bowie, Maryland
Conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Register for Updates
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433
Recruiting
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Gender:
ALL
Ages:
Between 45 years and 99 years
Trial Updated:
08/13/2025
Locations: MD Medical Research, Oxon Hill, Maryland
Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Register for Updates
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
NCT07019155
Recruiting
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases. Objective: To study the link between HHM and MDS/AML. Eligibility: People aged 1 mon... Read More
Gender:
ALL
Ages:
Between 1 month and 120 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Register for Updates
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618
Recruiting
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Galderma Investigational Site # 8012, Glendale, Maryland
Conditions: Prurigo Nodularis
Register for Updates
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930
Recruiting
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/13/2025
Locations: Research Site, Bethesda, Maryland
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Annapolis Internal Medicine, LLC, Annapolis, Maryland
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
NCT06742996
Recruiting
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/13/2025
Locations: Pharmasite Research, Inc. ( Site 0167), Baltimore, Maryland
Conditions: Alzheimer Disease, Dementia
Register for Updates
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140
Recruiting
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/13/2025
Locations: Centennial Medical Group, Columbia, Maryland
Conditions: COVID-19 SARS-CoV-2 Infection
Register for Updates